Commentary

Video

Dr Lin on Findings From the CARTITUDE-1 Trial in Relapsed/Refractory Multiple Myeloma

Author(s):

Yi Lin, MD, PhD, discusses findings from the primary analysis of the phase 1/2 CARTITUDE-1 trial of the BCMA-targeting CAR T-cell therapy ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

Yi Lin, MD, PhD, hematologist, oncologist, Mayo Clinic, discusses findings from the primary analysis of the phase 1/2 CARTITUDE-1 trial (NCT03548207) of the BCMA-targeting CAR T-cell therapy ciltacabtagene autoleucel (cilta-cel; Carvykti) in patients with relapsed/refractory multiple myeloma, highlighting how these preliminary findings contributed to the launch of a subgroup analysis evaluating response rates of patients who achieved minimal residual disease (MRD) negativity.

In 2022, the FDA approved cilta-cel for the treatment of patients with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. This regulatory decision was supported by findings from the single-arm CARTITUDE-1 trial, which evaluated the safety and efficacy of cilta-cel in patients who received a single dose of the CAR T-cell therapy and no maintenance therapy, Lin says.

Findings from the primary analysis of CARTITUDE-1 showed that at a median follow-up of 12.4 months (interquartile range, 10.6-15.2), the overall response rate was 97% (95% CI, 91.2%-99.4%), with a stringent complete response (sCR) rate of 67%. Additionally, the median duration of response (DOR) (95% CI, 15.9-not estimable [NE]) and the median progression-free survival ([PFS] 95% CI, 16.8-NE) were not reached. The 12-month PFS and overall survival rates were 77% (95% CI, 66.0%-84.3%) and 89% (95% CI, 80.2%-93.5%), respectively.

Furthermore, several patients who were evaluable for bone marrow MRD analysis achieved bone marrow MRD negativity, Lin explains. Of the 61 patients evaluable for MRD negativity, 91.8% achieved MRD negativity at any point during the trial.

An analysis of the efficacy outcomes and characteristics of the patients enrolled in CARTITUDE-1 who achieved sustained MRD negativity demonstrated that all patients with sustained MRD negativity for at least 6 months achieved sCR. Moreover, the patients with sustained MRD negativity achieved a longer DOR compared with the patients who did not have sustained MRD negativity.

Related Videos
Chun Chao, PhD, MS
Mikkael A. Sekeres, MD
Noa Biran, MD
Ranee Mehra, MD, professor, medicine, medical oncology; director, Head and Neck Medical Oncology, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland Medical System
Sumanta Kumar Pal, MD, FASCO, chair, Kidney and Bladder Cancer Disease Team; co-director, Kidney Cancer Program; professor, vice chair, Academic Affairs, Department of Medical Oncology & Therapeutics Research, City of Hope
Alfred L. Garfall, MD, MS
David Braun, MD, PhD
Anthony M. Hunter, MD
Amrita Krishnan, MD, City of Hope
Jonathan C. Trent, MD, PhD